Metabolic Disorders News and Research

RSS

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Glucocorticoid inhalation during pregnancy does not increase risk of diseases in offspring

Inhaled glucocorticoids for the treatment of asthma during pregnancy are not associated with an increased risk of most diseases in offspring, but may be a risk factor for endocrine and metabolic disturbances, according to a new study.

16 Dec 2011

Enrollment commences in Estech's HISTORIC-AF staged hybrid ablation study

Estech, a leader in minimally invasive cardiac surgery, announced today that the first three patients have been enrolled in the HISTORIC-AF European multi-center staged hybrid ablation clinical study.

5 Dec 2011

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

Renowned obstetrician receives March of Dimes 2011 Agnes Higgins award

A highly renowned obstetrician, professor and researcher who showed that babies born to obese and diabetic women have a higher risk of becoming overweight and developing diabetes or other metabolic health problems later in life, received the March of Dimes 2011 Agnes Higgins award for outstanding achievement in the field of maternal-fetal nutrition.

31 Oct 2011

Study uncovers mTOR's complex signaling pathway

Even yeast understand austerity. A finely tuned system evolved early on to help cells survive in a world where good times come as fast as they go. The system, a molecular switch found in organisms from yeast to humans, involves a nutrient-sensing protein that turns growth on in times of plenty and shuts it off when times are lean.

29 Oct 2011

Study provides details on genetics behind many metabolic diseases

In what is so far the largest investigation of its kind, researchers uncovered a wide range of new insights about common diseases and how they are affected by differences between two persons' genes. The results from this study could lead to highly targeted, individualized therapies.

27 Oct 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

A woman's pregnancy outcome can be an indicator of future health conditions

"A woman's pregnancy outcome can be an indicator of future health conditions," stated George R. Saade, M.D., president of the Society for Maternal-Fetal Medicine and professor of obstetrics and gynecology at The University of Texas Medical Branch in Galveston, Texas.

14 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Study describes new class of anti-diabetic compound that targets unique molecular switch

In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.

5 Sep 2011

IntraPace to launch new lifestyle management portal and support network at IFSO 2011 congress

IntraPace, Inc., the developer of the innovative abiliti implantable obesity management system, announced today that it will launch its new lifestyle management portal and support network this week at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in Hamburg, Germany.

30 Aug 2011

Low-glycemic foods, high protein intake reduce body weight and fat mass

A new study out of Madrid, Spain shows that low-glycemic foods, and moderately high-protein intake has been shown to reduce body weight and fat mass.

29 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

Mitochondrial genome undergoes random reorganisation during reprogramming

Induced pluripotent stem cells (iPS cells) are truly talented multi-taskers. They can reproduce almost all cell types and thus offer great hope in the fight against diseases like Alzheimer's and Parkinson's. However, it would appear that their use is not entirely without risk: during the reprogramming of body cells into iPS cells, disease-causing mutations can creep into the genetic material.

28 Jul 2011

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).

25 Jul 2011